Published in Gene Therapy Weekly, January 18th, 2007
"David U'Prichard has an acclaimed background in supporting and advancing innovative R&D programs within both life sciences companies and Big Pharma," stated Steven C. Mayer, chief executive officer of CoGenesys. "We are honored that David has joined our board. With his election, we have now completed the composition of the board, bringing to seven the number of directors."
U'Prichard commented, "CoGenesys has a strong heritage and broad platform for developing breakthrough products that can address real patient needs. I have...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.